Table 1 Cell signaling/cell interactions in tumor-infiltrating DCs
From: Deciphering tumor-infiltrating dendritic cells in the single-cell era
Cell type | Cancer type | Cell signaling/cell interaction |
|---|---|---|
cDC1 | LUAD | TCF-1+ CD8 T cell reservoir [76] |
| Â | HCC | Elevated HLA gene expression and robust antigen presentation [39] |
| Â | TNBC | Activation of CD4-CXCL13 and CD8-CXCL13 T cells[35] |
| Â | GBM | Recruitment by intracellular cytotoxic T cells [94] |
cDC2 | LUAD | Reduced pro-inflammatory gene expression and increased anti-inflammatory signals [43] |
pDC | LUAD | Upregulated expression of leukocyte immunoglobulin-like receptor genes, granzyme B production, and loss of CD86, CD83, CD80, and LAMP3 markers [9] |
|  | OSCC | Elevated IRF8 levels, reduced IFN-α production, and promotion of Treg cell proliferation [82] |
LAMP3+ DC | Pan-cancer | Elevated BTLA/CCL17 expression inducing Treg differentiation [10] |
|  | NSCLC | Enhancement of the population of IFNγ+ CD8+ T effector cells by IFN-γ-mediated IL-12 expression [85] |
| Â | NSCLC | Elevated PD-1 expression, upregulated by AXL receptor tyrosine kinase [85] |
| Â | NPC | Interaction with Treg cells via CTLA4 and CD80/CD86 [49] |
| Â | GC | Upregulation of the expression of IRF1, IRF2, NFKB1, and NFKB2 [84] |
moDC | Peritoneal ascites from ovarian cancer patients | Antigen cross-presentation via vacuolar pathway and induction of cytotoxic CD8+ T cell differentiation [90] |
| Â | Thyroid cancer, glioma, and breast cancer | Released TSH promotes proliferation, invasion, and immune escape [52] |